BioXcel Therapeutics Appoints Dr. Cedric Burg as Vice President and Head of Global Clinical Operations and Project Management...
June 13 2018 - 8:00AM
Building strong clinical team to effectively
support robust clinical programsDr. Burg to leverage his
international experience to expand the Company’s clinical trials
globally
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage
biopharmaceutical development company utilizing novel artificial
intelligence to identify the next wave of medicines across
neuroscience and immuno-oncology, today announced the appointment
of Dr. Cedric Burg as Vice President and Head of Global Clinical
Operations and Project Management. Dr. Burg will be responsible for
devising and executing BTI’s clinical operations strategy.
Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI,
commented, “We are pleased that Dr. Burg has accepted this crucial
and growing role. BTI is now at an important development stage
where its lead drug candidates are making significant advances with
data results from its first-in-human study of BXCL501 and
initiation of the clinical development of BXCL701, both expected in
the second half of 2018. We believe with Dr. Burg’s expertise in
clinical project management and experience in supporting multiple
successful global biotech companies in their clinical operations
will play a key role in driving BTI’s clinical programs forward
effectively while meeting critical timelines. Additionally, BTI is
making remarkable progress in expanding its strategic leadership by
building high performing teams with expertise in neuroscience and
immuno-oncology, making the company well positioned for long-term
growth.”
“I was very impressed by BTI’s innovative drug development
approach coupled with the robust pipeline candidates and strong
leadership,” said Dr. Burg. “I am excited to collaborate with the
management team at BTI on successfully executing our clinical
operations strategy. I look forward to contributing towards shaping
BTI’s clinical and commercialization strategy as we prepare to
advance the development of the two clinical assets and additional
compounds in the future.”
Dr. Burg has over 20 years of experience in clinical operations
and project management. Prior to joining BTI, Dr. Burg served as
the head of clinical operations at Rocket Pharmaceuticals, where he
was responsible for the overall clinical operations and program
management. Prior to joining Rocket Pharmaceuticals, Cedric served
as the vice president of clinical development and global project
management at Chiltern International, a global contract research
organization, where he was responsible for running the global late
phase group, clinical development programs and managing projects
across the company. Dr. Burg spent several years at Teva
Pharmaceuticals and played a key role in the execution and delivery
of worldwide clinical programs. As the Company’s deputy head of
global clinical operations, he was responsible for global
operations and clinical development strategy across several
geographies. Prior to that, Dr. Burg was the director of clinical
trials and director of medical affairs at Teva Pharmaceuticals for
Spain. Additionally, Dr. Burg has held key positions in clinical
trial management at Bristol Myers Squibb and Phidea, a contract
research organization.
Dr. Burg received a bachelor’s degree in biology and life
sciences from the American University, Washington D.C. and a
master’s degree in molecular and cellular biology from Rennes
University, France. He earned his Ph.D. in molecular and cellular
biology from Nantes University, France. He has authored several
peer-reviewed publications and conference presentations.
About BioXcel Therapeutics, Inc.:BioXcel
Therapeutics, Inc. is a clinical stage biopharmaceutical company
focused on drug development that utilizes novel artificial
intelligence to identify the next wave of medicines across
neuroscience and immuno-oncology. The company's drug re-innovation
approach leverages existing approved drugs and/or clinically
validated product candidates together with big data and proprietary
machine learning algorithms to identify new therapeutic indices.
The company's two most advanced clinical development programs are
BXCL501, a sublingual thin film formulation designed for acute
treatment of agitation resulting from neurological and psychiatric
disorders, and BXCL701, an immuno-oncology agent designed for
treatment of a rare form of prostate cancer and for treatment of
pancreatic cancer.
Contact Information:The Ruth GroupLee Roth/
Janhavi Mohite646-536-7012/
7026
lroth@theruthgroup.com/ jmohite@theruthgroup.com
Forward-Looking Statements:This press release
includes “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements in this press release include, but are not limited to,
statements that relate to the advancement and development of
BXCL501 and BXCL701, the commencement of clinical trials, the
availability of data from clinical trials and other information
that is not historical information. When used herein, words such as
“anticipate”, “being”, “will”, “plan”, “may”, “continue”, and
similar expressions are intended to identify forward-looking
statements. In addition, any statements or information that refer
to expectations, beliefs, plans, projections, objectives,
performance or other characterizations of future events or
circumstances, including any underlying assumptions, are
forward-looking. All forward-looking statements are based upon
BioXcel’s current expectations and various assumptions. BioXcel
believes there is a reasonable basis for its expectations and
beliefs, but they are inherently uncertain. BioXcel may not realize
its expectations, and its beliefs may not prove correct. Actual
results could differ materially from those described or implied by
such forward-looking statements as a result of various important
factors, including, without limitation, market conditions and the
factors described under the caption “Risk Factors” in BioXcel’s
prospectus dated March 7, 2018, and BioXcel’s other filings made
with the Securities and Exchange Commission. Consequently,
forward-looking statements should be regarded solely as BioXcel’s
current plans, estimates and beliefs. Investors should not place
undue reliance on forward-looking statements. BioXcel cannot
guarantee future results, events, levels of activity, performance
or achievements. BioXcel does not undertake and specifically
declines any obligation to update, republish, or revise any
forward-looking statements to reflect new information, future
events or circumstances or to reflect the occurrences of
unanticipated events, except as may be required by law.
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Sep 2023 to Sep 2024